本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Autolus Therapeutics PLC

1.94
+0.06003.19%
盤後1.88-0.0600-3.09%19:43 EDT
成交量:148.06萬
成交額:283.51萬
市值:5.16億
市盈率:-1.84
高:1.95
開:1.86
低:1.85
收:1.88
52周最高:2.58
52周最低:1.18
股本:2.66億
流通股本:1.04億
量比:0.81
換手率:1.42%
股息:- -
股息率:- -
每股收益(TTM):-1.0526
每股收益(LYR):-1.0804
淨資產收益率:-133.00%
總資產收益率:-25.44%
市淨率:6.90
市盈率(LYR):-1.80

資料載入中...

2023/12/11

重要事件披露

Form 8-K - Current report
2023/11/27

重要事件披露

Form 8-K - Current report
2023/11/09

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/09

重要事件披露

Form 8-K - Current report
2023/11/03

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/08/08

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/07/10

超過5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/03/20

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/03/07

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/02/14

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/13

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/12/19

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/12/13

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/12/13

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/10/05

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/05/13

SEC問詢函

CORRESP [Cover] - Correspondence